Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?
Top Cited Papers
- 26 May 2006
- journal article
- special perspectives
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 312 (5777) , 1171-1175
- https://doi.org/10.1126/science.1125950
Abstract
For more than 50 years, a major goal of research in cancer therapeutics has been to develop universally effective agents that render cancer cells more sensitive to cytotoxic chemotherapy without substantially increasing toxicity to normal cells. The results of recent clinical trials indicate that certain antiangiogenic drugs may produce this long-sought effect. Here, I describe three distinct mechanisms that may help to explain the chemosensitizing activity of these drugs: normalizing tumor vasculature, preventing rapid tumor cell repopulation, and augmenting the antivascular effects of chemotherapy. I then discuss how these potential mechanisms might be exploited to maximize therapeutic efficacy.Keywords
This publication has 42 references indexed in Scilit:
- Analysis of tumor‐associated stromal cells using SCID GFP transgenic mice: contribution of local and bone marrow‐derived host cellsThe FASEB Journal, 2006
- Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic CancerJournal of Clinical Oncology, 2005
- Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumorsPublished by Elsevier ,2005
- Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesisCancer Cell, 2005
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiationCancer Cell, 2004
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Journal of Clinical Oncology, 2003
- Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levelsAnnals of Oncology, 2002
- Aquaporins and the respiratory system: advice for a lung investigatorJournal of Clinical Investigation, 2000